Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma

Noriaki Morofuji, Hidenori Ojima, Hiroaki Onaya, Takuji Okusaka, Kazuaki Shimada, Yoshihiro Sakamoto, Minoru Esaki, Satoshi Nara, Tomoo Kosuge, Daisuke Asahina, Masahiko Ushigome, Nobuyoshi Hiraoka, Masato Nagino, Tadashi Kondo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Cholangiocarcinoma is one of the deadliest malignancies worldwide. Recent studies reported that treatment with gemcitabine was effective in prolonging survival. However, as the treatment only benefited a limited subset of patients, selection of patients before treatment is required. To discover biomarkers predictive of the response to gemcitabine treatment in cholangiocarcinoma, we examined the proteome of three types of material resource; ten cell lines, nine xenografts and nine surgically resected primary tumors from patients who exhibited different response to gemcitabine treatment. Two-dimensional difference gel electrophoresis generated quantitative protein expression profiles including 3571 protein spots. We detected 172 protein spots with significant correlation with response to gemcitabine treatment. All proteins corresponding to these 172 protein spots were identified by mass spectrometry. We found that the macrophage-capping protein (CapG) was associated with response to gemcitabin treatment in all three types of material source. Immunohistochemical validation in an additional set of 196 cholangiocarcinoma cases revealed that CapG expression was associated with lymphatic invasion status and overall survival. Multivariate analysis showed that CapG protein expression was an independent prognostic factor for overall survival. In conclusion, CapG was identified as a novel candidate biomarker to predict response to gemcitabine treatment and survival in cholangiocarcinoma.

Original languageEnglish
Pages (from-to)1577-1589
Number of pages13
JournalJournal of Proteomics
Volume75
Issue number5
DOIs
Publication statusPublished - 2012 Feb 16
Externally publishedYes

Fingerprint

gemcitabine
Cholangiocarcinoma
Macrophages
Biomarkers
Tissue
Proteins
Survival
Therapeutics
Patient treatment
Two-Dimensional Difference Gel Electrophoresis
Proteome
Electrophoresis
Heterografts
Mass spectrometry
Tumors
Patient Selection
Gels
Cells
Mass Spectrometry
Neoplasms

Keywords

  • Biomarker
  • Cholangiocarcinoma
  • Gemcitabine
  • Macrophage-capping protein (CapG)
  • Two-dimensional difference gel electrophoresis

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics

Cite this

Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma. / Morofuji, Noriaki; Ojima, Hidenori; Onaya, Hiroaki; Okusaka, Takuji; Shimada, Kazuaki; Sakamoto, Yoshihiro; Esaki, Minoru; Nara, Satoshi; Kosuge, Tomoo; Asahina, Daisuke; Ushigome, Masahiko; Hiraoka, Nobuyoshi; Nagino, Masato; Kondo, Tadashi.

In: Journal of Proteomics, Vol. 75, No. 5, 16.02.2012, p. 1577-1589.

Research output: Contribution to journalArticle

Morofuji, N, Ojima, H, Onaya, H, Okusaka, T, Shimada, K, Sakamoto, Y, Esaki, M, Nara, S, Kosuge, T, Asahina, D, Ushigome, M, Hiraoka, N, Nagino, M & Kondo, T 2012, 'Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma', Journal of Proteomics, vol. 75, no. 5, pp. 1577-1589. https://doi.org/10.1016/j.jprot.2011.11.030
Morofuji, Noriaki ; Ojima, Hidenori ; Onaya, Hiroaki ; Okusaka, Takuji ; Shimada, Kazuaki ; Sakamoto, Yoshihiro ; Esaki, Minoru ; Nara, Satoshi ; Kosuge, Tomoo ; Asahina, Daisuke ; Ushigome, Masahiko ; Hiraoka, Nobuyoshi ; Nagino, Masato ; Kondo, Tadashi. / Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma. In: Journal of Proteomics. 2012 ; Vol. 75, No. 5. pp. 1577-1589.
@article{ccff50b7d36245df9d8ccbca1fb2caa4,
title = "Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma",
abstract = "Cholangiocarcinoma is one of the deadliest malignancies worldwide. Recent studies reported that treatment with gemcitabine was effective in prolonging survival. However, as the treatment only benefited a limited subset of patients, selection of patients before treatment is required. To discover biomarkers predictive of the response to gemcitabine treatment in cholangiocarcinoma, we examined the proteome of three types of material resource; ten cell lines, nine xenografts and nine surgically resected primary tumors from patients who exhibited different response to gemcitabine treatment. Two-dimensional difference gel electrophoresis generated quantitative protein expression profiles including 3571 protein spots. We detected 172 protein spots with significant correlation with response to gemcitabine treatment. All proteins corresponding to these 172 protein spots were identified by mass spectrometry. We found that the macrophage-capping protein (CapG) was associated with response to gemcitabin treatment in all three types of material source. Immunohistochemical validation in an additional set of 196 cholangiocarcinoma cases revealed that CapG expression was associated with lymphatic invasion status and overall survival. Multivariate analysis showed that CapG protein expression was an independent prognostic factor for overall survival. In conclusion, CapG was identified as a novel candidate biomarker to predict response to gemcitabine treatment and survival in cholangiocarcinoma.",
keywords = "Biomarker, Cholangiocarcinoma, Gemcitabine, Macrophage-capping protein (CapG), Two-dimensional difference gel electrophoresis",
author = "Noriaki Morofuji and Hidenori Ojima and Hiroaki Onaya and Takuji Okusaka and Kazuaki Shimada and Yoshihiro Sakamoto and Minoru Esaki and Satoshi Nara and Tomoo Kosuge and Daisuke Asahina and Masahiko Ushigome and Nobuyoshi Hiraoka and Masato Nagino and Tadashi Kondo",
year = "2012",
month = "2",
day = "16",
doi = "10.1016/j.jprot.2011.11.030",
language = "English",
volume = "75",
pages = "1577--1589",
journal = "Journal of Proteomics",
issn = "1874-3919",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma

AU - Morofuji, Noriaki

AU - Ojima, Hidenori

AU - Onaya, Hiroaki

AU - Okusaka, Takuji

AU - Shimada, Kazuaki

AU - Sakamoto, Yoshihiro

AU - Esaki, Minoru

AU - Nara, Satoshi

AU - Kosuge, Tomoo

AU - Asahina, Daisuke

AU - Ushigome, Masahiko

AU - Hiraoka, Nobuyoshi

AU - Nagino, Masato

AU - Kondo, Tadashi

PY - 2012/2/16

Y1 - 2012/2/16

N2 - Cholangiocarcinoma is one of the deadliest malignancies worldwide. Recent studies reported that treatment with gemcitabine was effective in prolonging survival. However, as the treatment only benefited a limited subset of patients, selection of patients before treatment is required. To discover biomarkers predictive of the response to gemcitabine treatment in cholangiocarcinoma, we examined the proteome of three types of material resource; ten cell lines, nine xenografts and nine surgically resected primary tumors from patients who exhibited different response to gemcitabine treatment. Two-dimensional difference gel electrophoresis generated quantitative protein expression profiles including 3571 protein spots. We detected 172 protein spots with significant correlation with response to gemcitabine treatment. All proteins corresponding to these 172 protein spots were identified by mass spectrometry. We found that the macrophage-capping protein (CapG) was associated with response to gemcitabin treatment in all three types of material source. Immunohistochemical validation in an additional set of 196 cholangiocarcinoma cases revealed that CapG expression was associated with lymphatic invasion status and overall survival. Multivariate analysis showed that CapG protein expression was an independent prognostic factor for overall survival. In conclusion, CapG was identified as a novel candidate biomarker to predict response to gemcitabine treatment and survival in cholangiocarcinoma.

AB - Cholangiocarcinoma is one of the deadliest malignancies worldwide. Recent studies reported that treatment with gemcitabine was effective in prolonging survival. However, as the treatment only benefited a limited subset of patients, selection of patients before treatment is required. To discover biomarkers predictive of the response to gemcitabine treatment in cholangiocarcinoma, we examined the proteome of three types of material resource; ten cell lines, nine xenografts and nine surgically resected primary tumors from patients who exhibited different response to gemcitabine treatment. Two-dimensional difference gel electrophoresis generated quantitative protein expression profiles including 3571 protein spots. We detected 172 protein spots with significant correlation with response to gemcitabine treatment. All proteins corresponding to these 172 protein spots were identified by mass spectrometry. We found that the macrophage-capping protein (CapG) was associated with response to gemcitabin treatment in all three types of material source. Immunohistochemical validation in an additional set of 196 cholangiocarcinoma cases revealed that CapG expression was associated with lymphatic invasion status and overall survival. Multivariate analysis showed that CapG protein expression was an independent prognostic factor for overall survival. In conclusion, CapG was identified as a novel candidate biomarker to predict response to gemcitabine treatment and survival in cholangiocarcinoma.

KW - Biomarker

KW - Cholangiocarcinoma

KW - Gemcitabine

KW - Macrophage-capping protein (CapG)

KW - Two-dimensional difference gel electrophoresis

UR - http://www.scopus.com/inward/record.url?scp=84856352263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856352263&partnerID=8YFLogxK

U2 - 10.1016/j.jprot.2011.11.030

DO - 10.1016/j.jprot.2011.11.030

M3 - Article

C2 - 22155129

AN - SCOPUS:84856352263

VL - 75

SP - 1577

EP - 1589

JO - Journal of Proteomics

JF - Journal of Proteomics

SN - 1874-3919

IS - 5

ER -